Plain-English translation of NCT06082037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help people whose transplanted lungs are slowly failing despite already taking standard anti-rejection medicines. About 180 adults will take part, with half receiving the new medication and half receiving a placebo (a fake pill) — but no one will know which they're getting. The trial will last up to 6 months or longer for those who continue into an extended phase.
Even with current anti-rejection treatments, some lung transplant recipients experience progressive rejection that can threaten their transplant. This medication is being tested because early research suggests it might slow or stop this rejection process in people who aren't responding well enough to existing therapies.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic up to 10–16 times over 6 months to a year, depending on whether you continue into the extended phase. At each visit, you'll have breathing tests, blood work, and check-ins with the study team. You'll take one pill by mouth every day — either the new medication or a placebo — in addition to your regular anti-rejection medicines. If the medication appears to be working well, you may be invited to continue taking it in a longer follow-up phase with visits every 3 months.
AI-generated summary from trial data · Oct 4, 2026 · Not medical advice
United States